JP4426329B2 - ムコ多糖積層脂質膜、膜透過性測定用フィルタ、膜透過性測定装置、膜透過性測定用キット、膜透過性評価方法及び被検物質のスクリーニング方法 - Google Patents
ムコ多糖積層脂質膜、膜透過性測定用フィルタ、膜透過性測定装置、膜透過性測定用キット、膜透過性評価方法及び被検物質のスクリーニング方法 Download PDFInfo
- Publication number
- JP4426329B2 JP4426329B2 JP2004031362A JP2004031362A JP4426329B2 JP 4426329 B2 JP4426329 B2 JP 4426329B2 JP 2004031362 A JP2004031362 A JP 2004031362A JP 2004031362 A JP2004031362 A JP 2004031362A JP 4426329 B2 JP4426329 B2 JP 4426329B2
- Authority
- JP
- Japan
- Prior art keywords
- mucopolysaccharide
- membrane
- lipid membrane
- laminated
- test substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012528 membrane Substances 0.000 title claims description 201
- 229920002683 Glycosaminoglycan Polymers 0.000 title claims description 125
- 150000002632 lipids Chemical class 0.000 title claims description 116
- 238000012360 testing method Methods 0.000 title claims description 56
- 230000035699 permeability Effects 0.000 title claims description 48
- 238000005259 measurement Methods 0.000 title claims description 12
- 238000011156 evaluation Methods 0.000 title claims description 11
- 238000000034 method Methods 0.000 title description 24
- 238000013513 substance screening Methods 0.000 title description 2
- 239000000126 substance Substances 0.000 claims description 57
- 229920000642 polymer Polymers 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 24
- 150000003904 phospholipids Chemical class 0.000 claims description 19
- 230000007704 transition Effects 0.000 claims description 14
- 239000012466 permeate Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- -1 sialic acid polysaccharide Chemical class 0.000 claims description 10
- 238000003860 storage Methods 0.000 claims description 7
- 229920000936 Agarose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 229920002678 cellulose Polymers 0.000 claims description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 3
- 238000000691 measurement method Methods 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 description 34
- 239000003814 drug Substances 0.000 description 12
- 230000002209 hydrophobic effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- XWJBRBSPAODJER-UHFFFAOYSA-N 1,7-octadiene Chemical compound C=CCCCCC=C XWJBRBSPAODJER-UHFFFAOYSA-N 0.000 description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 5
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 5
- 150000003905 phosphatidylinositols Chemical class 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 229920000954 Polyglycolide Polymers 0.000 description 4
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000004633 polyglycolic acid Substances 0.000 description 4
- 239000004626 polylactic acid Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 230000036186 satiety Effects 0.000 description 4
- 235000019627 satiety Nutrition 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 229920005615 natural polymer Polymers 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000003178 parallel artificial membrane permeation assay Methods 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- NLDGJRWPPOSWLC-UHFFFAOYSA-N deca-1,9-diene Chemical compound C=CCCCCCCC=C NLDGJRWPPOSWLC-UHFFFAOYSA-N 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000006903 response to temperature Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Laminated Bodies (AREA)
Description
ムコ多糖とは、具体的には、ムチン、コンドロイチン硫酸、ヒアルロン酸、シアル酸多糖、ヘパリン、ヘパチリン硫酸、ケラト硫酸、キチン及びそれらの混合物をいう。
実施例1に係るムコ多糖積層脂質膜を図5に示す工程図に従って作製した。
先ず、コンドロイチン硫酸(シグマ社より購入)とアガロース(低融点)(シグマ社より購入)をpH6.0リン酸緩衝液に添加して、加熱溶解し、各々を1%含有するゲル(以下ムコ多糖ゲル)を作成した。
実施例1において、親水性フィルタ層を構せずにムコ多糖ゲルを添加した。その場合の外観を、図7(a)に示す。ムコ多糖ゲル10μL添加では、疎水性フィルタとの表面張力により液滴状になってしまった。均一に添加するには75μLを必要とした(図7(b))。75μLを添加した場合のムコ多糖ゲルの膜厚は約3000μmであった。
30%のDMSOを含むpH7.4リン酸緩衝液を96穴テフロン(登録商標)製アクセプタープレート(日本ミリポア社より購入)に300μL添加した。アクセプタープレート上に、実施例1と同様の方法(但し、フォスファチジルコリン0.8%(w/w)、フォスファチジルエタノールアミン0.8%(w/w)、フォスファチジルセリン0.2%(w/w)、フォスファチジルイノシトール0.2%(w/w)、コレステロール1.0%(w/w)、1,7−オクタジエン97.0%(w/w)からなるリン脂質有機溶媒溶液を利用)により作成したムコ多糖層−人工リン脂質膜を底部に有するプレートを装着した(ドナープレート)。尚、ムコ多糖層−人工リン脂質膜を作成する際、ムコ多糖ゲル添加量を7.5μLから75μLまで変化させてムコ多糖層−人工リン脂質膜を作成した。また、同時に対照として、ミリポア96穴メンブレフィルターに、フォスファチジルコリン0.8%(w/w)、フォスファチジルエタノールアミン0.8%(w/w)、フォスファチジルセリン0.2%(w/w)、フォスファチジルイノシトール0.2%(w/w)、コレステロール1.0%(w/w)、1,7−オクタジエン97.0%(w/w)からなるリン脂質有機溶媒溶液のみを添加して作成した、ムコ多糖層を有しない人工リン脂質膜も作成した。
30%のDMSOを含むpH7.4リン酸緩衝液を96穴テフロン(登録商標)製アクセプタープレートに300μL添加した。アクセプタープレート上に、実施例1と同様の方法((但し、フォスファチジルコリン0.8%(w/w)、フォスファチジルエタノールアミン0.8%(w/w)、フォスファチジルセリン0.2%(w/w)、フォスファチジルイノシトール0.2%(w/w)、コレステロール1.0%(w/w)、1,7−オクタジエン97.0%(w/w)からなるリン脂質有機溶媒溶液を利用)により作成したムコ多糖層−人工リン脂質膜を底部に有するプレート(ドナープレート)を装着した。尚、ムコ多糖層−人工リン脂質膜を作成する際、対照として、ミリポア96穴メンブレフィルターに、フォスファチジルコリン0.8%(w/w)、フォスファチジルエタノールアミン0.8%(w/w)、フォスファチジルセリン0.2%(w/w)、フォスファチジルイノシトール0.2%(w/w)、コレステロール1.0%(w/w)、1,7−オクタジエン97.0%(w/w)からなるリン脂質有機溶媒溶液のみを添加して作成した、ムコ多糖層を有しない人工リン脂質膜も作成した。
Claims (14)
- 脂質膜と、
該脂質膜上に形成された、ムコ多糖を含むゲル状ポリマーを含浸した親水性フィルタを含む親水性フィルタ層と、を備えるムコ多糖積層脂質膜。 - 前記親水性フィルタ層が前記脂質膜の一方面上に形成されている、請求項1記載のムコ多糖積層脂質膜。
- 前記親水性フィルタ層は、
ゾル−ゲル転移しうるポリマーとムコ多糖とを含む混合物を、当該ポリマーをゾル状にした状態で前記親水性フィルタに含浸させ、ゾル状の当該ポリマーをゲル状ポリマーに転移させて形成させた層である、請求項1又は2記載のムコ多糖積層脂質膜。 - 前記混合物が水溶液である、請求項3記載のムコ多糖積層脂質膜。
- 前記ゾル−ゲル転移しうるポリマーがアガロースである、請求項3又は4記載のムコ多糖積層脂質膜。
- 前記ムコ多糖が、ムチン、コンドロイチン硫酸、ヒアルロン酸、シアル酸多糖、ヘパリン、ヘパチリン硫酸、ケラト硫酸及びキチンからなる群より選ばれる少なくとも1種である、請求項1〜5記載のムコ多糖積層脂質膜。
- 前記親水性フィルタが、紙フィルタ、セルロースフィルタ及びセルロースフィルタ誘導体からなる群より選ばれる少なくとも1種である、請求項1〜6のいずれか一項に記載のムコ多糖積層脂質膜。
- 前記脂質膜は人工リン脂質膜である、請求項1〜7のいずれか一項に記載のムコ多糖積層脂質膜。
- 前記親水性フィルタ層の厚さは100μm〜500μmである、請求項1〜8のいずれか一項に記載のムコ多糖積層脂質膜。
- 請求項1〜9のいずれか一項に記載のムコ多糖積層脂質膜からなる膜透過性測定用フィルタ。
- 請求項1〜9のいずれか一項に記載のムコ多糖積層脂質膜と、
前記ムコ多糖積層脂質膜の一方面上に配置され当該ムコ多糖積層脂質膜に接するように被検物質を収容する被検物質収容容器と、
前記ムコ多糖積層脂質膜の他方面上に配置され当該ムコ多糖積層脂質膜からの透過物を収容する透過物収容容器と、を備える、膜透過性測定装置。 - 請求項1〜9のいずれか一項に記載のムコ多糖積層脂質膜と、
前記ムコ多糖積層脂質膜の一方面上に配置して当該ムコ多糖積層脂質膜に接するように被検物質を収容するための被検物質収容容器と、
前記ムコ多糖積層脂質膜の他方面上に配置して当該ムコ多糖積層脂質膜からの透過物を収容するための透過物収容容器と、から少なくとも構成される膜透過性測定用キット。 - 請求項1〜9のいずれか一項に記載のムコ多糖積層脂質膜の一方面に被検物質を含む溶液が接するように配置し、当該ムコ多糖積層脂質膜の他方面に前記被検物質を含まない溶液が接するように配置して、
所定時間経過後に、前記他方面側の溶液における前記被検物質の量及び/又は前記一方面側の溶液における前記被検物質の量を測定することにより、被検物質の膜透過性を測定する膜透過性評価方法。 - 請求項13記載の膜透過性測定方法により複数の被検物質の膜透過性を測定する測定工程と、
前記測定工程で得られた膜透過性のデータに基づいて、前記複数の被検物質から所望の被検物質を選択する選択工程と、を含む、被検物質のスクリーニング方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004031362A JP4426329B2 (ja) | 2004-02-06 | 2004-02-06 | ムコ多糖積層脂質膜、膜透過性測定用フィルタ、膜透過性測定装置、膜透過性測定用キット、膜透過性評価方法及び被検物質のスクリーニング方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004031362A JP4426329B2 (ja) | 2004-02-06 | 2004-02-06 | ムコ多糖積層脂質膜、膜透過性測定用フィルタ、膜透過性測定装置、膜透過性測定用キット、膜透過性評価方法及び被検物質のスクリーニング方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005221442A JP2005221442A (ja) | 2005-08-18 |
JP4426329B2 true JP4426329B2 (ja) | 2010-03-03 |
Family
ID=34997190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004031362A Expired - Lifetime JP4426329B2 (ja) | 2004-02-06 | 2004-02-06 | ムコ多糖積層脂質膜、膜透過性測定用フィルタ、膜透過性測定装置、膜透過性測定用キット、膜透過性評価方法及び被検物質のスクリーニング方法 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4426329B2 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8986781B2 (en) * | 2005-10-27 | 2015-03-24 | Corning Incorporated | Immobilized multi-layer artificial membrane for permeability measurements (PAMPA) |
JP2018503065A (ja) * | 2014-11-17 | 2018-02-01 | スードダンスク ウニヴァシテーツSyddansk Universitet | 調整可能な生体模倣特性を備えた薬物透過性評価アセンブリ |
CN111495207A (zh) * | 2020-04-23 | 2020-08-07 | 北京赛诺膜技术有限公司 | 一种聚合物超滤膜的亲水改性方法 |
-
2004
- 2004-02-06 JP JP2004031362A patent/JP4426329B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2005221442A (ja) | 2005-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Garala et al. | Formulation and in-vitro characterization of monolithic matrix transdermal systems using HPMC/Eudragit S 100 polymer blends | |
Han et al. | Nanopore arrays for stable and functional free‐standing lipid bilayers | |
Bai et al. | Stable emulsions formed by self-assembly of interfacial networks of dipeptide derivatives | |
Freag et al. | Laminated chitosan-based composite sponges for transmucosal delivery of novel protamine-decorated tripterine phytosomes: ex-vivo mucopenetration and in-vivo pharmacokinetic assessments | |
Refai et al. | Development and characterization of polymer-coated liposomes for vaginal delivery of sildenafil citrate | |
Liu et al. | Influence of process parameters on the size distribution of PLA microcapsules prepared by combining membrane emulsification technique and double emulsion-solvent evaporation method | |
Liu et al. | Preparation of insulin-loaded PLA/PLGA microcapsules by a novel membrane emulsification method and its release in vitro | |
CA2087435C (en) | Use of interfacially-polymerized membranes in delivery devices | |
Bernards et al. | Nanostructured thin film polymer devices for constant-rate protein delivery | |
Brandl et al. | Oromucosal drug delivery: Trends in in-vitro biopharmaceutical assessment of new chemical entities and formulations | |
EP1730516A1 (en) | Method and device for evaluation of pharmaceutical compositions | |
Caschera et al. | Stable vesicles composed of monocarboxylic or dicarboxylic fatty acids and trimethylammonium amphiphiles | |
Rocha-García et al. | Gelatin-based porous silicon hydrogel composites for the controlled release of tramadol | |
Ramadurai et al. | Microcavity-Supported Lipid Bilayers; Evaluation of Drug–Lipid Membrane Interactions by Electrochemical Impedance and Fluorescence Correlation Spectroscopy | |
Korobko et al. | Encapsulation of DNA by cationic diblock copolymer vesicles | |
Shivalingam et al. | Formulation and evaluation of transdermal patches of pantoprazole sodium | |
JP4426329B2 (ja) | ムコ多糖積層脂質膜、膜透過性測定用フィルタ、膜透過性測定装置、膜透過性測定用キット、膜透過性評価方法及び被検物質のスクリーニング方法 | |
Kshirsagar et al. | Development and evaluation of carvedilol-loaded transdermal drug delivery system: In-vitro and in-vivo characterization study | |
JP2013527794A (ja) | ヒト皮膚様透過性を有するポリマー膜およびこの使用 | |
Göse et al. | Design of a homogeneous multifunctional supported lipid membrane on layer-by-layer coated microcarriers | |
JP5345078B2 (ja) | 脂質二重膜、それを形成するために用いられる自己支持性フィルム及びそれを具備するマイクロ流路デバイス | |
Reddy et al. | Development and in-vivo characterization of novel trans buccal formulations of Amiloride hydrochloride | |
EP3221687B1 (en) | Assembly for assessing drug permeability with adjustable biomimetic properties | |
Pereira et al. | Cationic bilayers on polymeric particles: effect of low NaCl concentration on surface coverage | |
Olariu et al. | Evaluation of the barrierpotential of somesynthetic membranes in testing the in vitro tenoxicam release from hydrogels, using the experimental model with Franz diffusion cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070201 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090313 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091201 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4426329 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131218 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |